Skip to content
2000
image of A Single-arm, Open-label, Phase Ib Clinical Study Evaluating the Efficacy andSafetyofDurvalumabinCombinationwithAlbumin-bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-small Cell Lung Cancer

Abstract

Objective

This study aimed to explore the clinical efficacy and safety of durvalumab combined with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy for resectable stage III Non-small Cell Lung Cancer (NSCLC).

Methods

A single-arm open-label phase Ib study was conducted. A total of 40 patients with driver gene-negative resectable stage III NSCLC were enrolled. All patients received neoadjuvant treatment with durvalumab in combination with albumin-bound paclitaxel and carboplatin. The clinical efficacy, Major Pathological Response (MPR), Complete Pathological Response (pCR), and safety were assessed. Flow cytometry was used to detect the expression of programmed cell death receptor 1 (PD-1) on total T, helper T, and cytotoxic T lymphocytes in peripheral blood before and after neoadjuvant treatment. Adverse reactions during the treatment were recorded. Disease-free Survival (DFS) and Overall Survival (OS) curves were constructed.

Results

After the neoadjuvant treatment, the overall Objective Response Rate (ORR) in the 40 patients with NSCLC was 65.00%. MPR was achieved in 27 patients (67.50%), and pCR was achieved in nine patients (22.50%). The expression levels of PD-1 on total T, helper T, and cytotoxic T lymphocytes in patients with NSCLC significantly decreased after treatment (all < 0.05). The most common adverse events were hair loss (47.50%), nausea and vomiting (42.50%), and fatigue (40.00%). The majority of adverse events were grades 1 and 2, with a small number of events being grades 3 and 4. At the end of the follow-up period, the average DFS was 21.49 ± 0.99 months, and the average OS was 24.79 ± 0.53 months.

Conclusion

Neoadjuvant treatment with durvalumab combined with albumin-bound paclitaxel and carboplatin as first-line therapy for driver gene-negative stage III NSCLC achieved a high pathological response rate and improved immune function. It is expected to extend patient survival with good tolerability.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/pra/10.2174/0115748928304000240429120252
2025-01-06
2025-09-12

  • From This Site

    /content/journals/pra/10.2174/0115748928304000240429120252
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660 33538338
    [Google Scholar]
  2. Shankar A. Saini D. Dubey A. Roy S. Bharati S.J. Singh N. Khanna M. Prasad C.P. Singh M. Kumar S. Sirohi B. Seth T. Rinki M. Mohan A. Guleria R. Rath G.K. Feasibility of lung cancer screening in developing countries: Challenges, opportunities and way forward. Transl. Lung Cancer Res. 2019 8 S1 S106 S121 10.21037/tlcr.2019.03.03 31211111
    [Google Scholar]
  3. Ettinger D.S. Wood D.E. Aisner D.L. Akerley W. Bauman J.R. Bharat A. Bruno D.S. Chang J.Y. Chirieac L.R. D’Amico T.A. DeCamp M. Dilling T.J. Dowell J. Gettinger S. Grotz T.E. Gubens M.A. Hegde A. Lackner R.P. Lanuti M. Lin J. Loo B.W. Lovly C.M. Maldonado F. Massarelli E. Morgensztern D. Ng T. Otterson G.A. Pacheco J.M. Patel S.P. Riely G.J. Riess J. Schild S.E. Shapiro T.A. Singh A.P. Stevenson J. Tam A. Tanvetyanon T. Yanagawa J. Yang S.C. Yau E. Gregory K. Hughes M. Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 2022 20 5 497 530 10.6004/jnccn.2022.0025 35545176
    [Google Scholar]
  4. Chen P. Liu Y. Wen Y. Zhou C. Non‐small cell lung cancer in China. Cancer Commun. 2022 42 10 937 970 10.1002/cac2.12359 36075878
    [Google Scholar]
  5. Abu Rous F. Singhi E.K. Sridhar A. Faisal M.S. Desai A. Lung cancer treatment advances in 2022. Cancer Invest. 2023 41 1 12 24 10.1080/07357907.2022.2119479 36036470
    [Google Scholar]
  6. Alexander M. Kim S.Y. Cheng H. Update 2020: Management of non-small cell lung cancer. Lung 2020 198 6 897 907 10.1007/s00408‑020‑00407‑5 33175991
    [Google Scholar]
  7. Duma N. Santana-Davila R. Molina J.R. Non–small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin. Proc. 2019 94 8 1623 1640 10.1016/j.mayocp.2019.01.013 31378236
    [Google Scholar]
  8. Lee J.M. McNamee C.J. Toloza E. Negrao M.V. Lin J. Shum E. Cummings A.L. Kris M.G. Sepesi B. Bara I. Kurtsikidze N. Schulze K. Ngiam C. Chaft J.E. Neoadjuvant targeted therapy in resectable NSCLC: Current and future perspectives. J. Thorac. Oncol. 2023 18 11 1458 1477 10.1016/j.jtho.2023.07.006 37451404
    [Google Scholar]
  9. Jazieh A.R. Zeitouni M. Alghamdi M. Alrujaib M. Lotfi S. Abu Daff S. Alomair A. Alshehri S. Alhusaini H. Allehebi A. Ansari J. Alnassar M. Jafar H. Alfarsi A. Abdelhafeez N. Alkattan K. Management guidelines for stage III non-small cell lung cancer. Crit. Rev. Oncol. Hematol. 2021 157 103144 10.1016/j.critrevonc.2020.103144 33254035
    [Google Scholar]
  10. Doroshow D.B. Sanmamed M.F. Hastings K. Politi K. Rimm D.L. Chen L. Melero I. Schalper K.A. Herbst R.S. Immunotherapy in non–small cell lung cancer: Facts and hopes. Clin. Cancer Res. 2019 25 15 4592 4602 10.1158/1078‑0432.CCR‑18‑1538 30824587
    [Google Scholar]
  11. Chen Y. Gao M. Huang Z. Yu J. Meng X. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: A focus on the mechanisms, advances, and future challenges. J. Hematol. Oncol. 2020 13 1 105 10.1186/s13045‑020‑00940‑z 32723363
    [Google Scholar]
  12. Geng Y. Zhang Q. Feng S. Li C. Wang L. Zhao X. Yang Z. Li Z. Luo H. Liu R. Lu B. Wang X. Safety and efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: A systematic review and meta‐analysis. Cancer Med. 2021 10 4 1222 1239 10.1002/cam4.3718 33465302
    [Google Scholar]
  13. Rothschild S.I. Zippelius A. Eboulet E.I. Prince S.S. Betticher D. Bettini A. Früh M. Joerger M. Lardinois D. Gelpke H. Mauti L.A. Britschgi C. Weder W. Peters S. Mark M. Cathomas R. Ochsenbein A.F. Janthur W.D. Waibel C. Mach N. Froesch P. Buess M. Bohanes P. Godar G. Rusterholz C. Gonzalez M. Pless M. SAKK 16/14: Durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non–small-cell lung cancer—A multicenter single-arm phase II trial. J. Clin. Oncol. 2021 39 26 2872 2880 10.1200/JCO.21.00276 34251873
    [Google Scholar]
  14. Shu C.A. Gainor J.F. Awad M.M. Chiuzan C. Grigg C.M. Pabani A. Garofano R.F. Stoopler M.B. Cheng S.K. White A. Lanuti M. D’Ovidio F. Bacchetta M. Sonett J.R. Saqi A. Rizvi N.A. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: An open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020 21 6 786 795 10.1016/S1470‑2045(20)30140‑6 32386568
    [Google Scholar]
  15. Girard N. Bar J. Garrido P. Garassino M.C. McDonald F. Mornex F. Filippi A.R. Smit H.J.M. Peters S. Field J.K. Christoph D.C. Sibille A. Fietkau R. Haakensen V.D. Chouaid C. Markman B. Hiltermann T.J.N. Taus A. Sawyer W. Allen A. Chander P. Licour M. Solomon B. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: Findings from the PACIFIC-R study. J. Thorac. Oncol. 2023 18 2 181 193 10.1016/j.jtho.2022.10.003 36307040
    [Google Scholar]
  16. Antonia S.J. Villegas A. Daniel D. Vicente D. Murakami S. Hui R. Kurata T. Chiappori A. Lee K.H. de Wit M. Cho B.C. Bourhaba M. Quantin X. Tokito T. Mekhail T. Planchard D. Kim Y.C. Karapetis C.S. Hiret S. Ostoros G. Kubota K. Gray J.E. Paz-Ares L. de Carpeño C.J. Finn F.C. Reck M. Vansteenkiste J. Spigel D.R. Wadsworth C. Melillo G. Taboada M. Dennis P.A. Özgüroğlu M. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. 2018 379 24 2342 2350 10.1056/NEJMoa1809697 30280658
    [Google Scholar]
  17. Argote A.J. Dasanu C.A. Durvalumab in cancer medicine: A comprehensive review. Expert Opin. Biol. Ther. 2019 19 9 927 935 10.1080/14712598.2019.1635115 31272242
    [Google Scholar]
  18. Miyanaga A. Asahina H. Watanabe S. Shukuya T. Tsubata Y. Hosomi Y. Sugawara S. Maemondo M. Okano T. Morita S. Matsuyama K. Kobayashi K. Seike M. A phase I/II study of necitumumab plus pembrolizumab, nab-paclitaxel, and carboplatin for previously untreated advanced squamous non–small cell lung cancer study: (NEJ048A/NEXUS). Clin. Lung Cancer 2023 24 4 371 375 10.1016/j.cllc.2023.01.008 36849264
    [Google Scholar]
  19. Chai Y. Wu X. Zou Y. Zhang X. Bai H. Dong M. Duan J. Immunotherapy combined with chemotherapy versus chemotherapy alone as the first‐line treatment of PD‐L1 ‐negative and driver‐gene‐negative advanced nonsquamous non‐small‐cell lung cancer: An updated systematic review and meta‐analysis. Thorac. Cancer 2022 13 22 3124 3132 10.1111/1759‑7714.14664 36168110
    [Google Scholar]
  20. Eisenhauer E.A. Therasse P. Bogaerts J. Schwartz L.H. Sargent D. Ford R. Dancey J. Arbuck S. Gwyther S. Mooney M. Rubinstein L. Shankar L. Dodd L. Kaplan R. Lacombe D. Verweij J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 2009 45 2 228 247 10.1016/j.ejca.2008.10.026 19097774
    [Google Scholar]
  21. Hellmann M.D. Chaft J.E. William W.N. Jr Rusch V. Pisters K.M.W. Kalhor N. Pataer A. Travis W.D. Swisher S.G. Kris M.G. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: Proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014 15 1 e42 e50 10.1016/S1470‑2045(13)70334‑6 24384493
    [Google Scholar]
  22. Travis W.D. Dacic S. Wistuba I. Sholl L. Adusumilli P. Bubendorf L. Bunn P. Cascone T. Chaft J. Chen G. Chou T.Y. Cooper W. Erasmus J.J. Ferreira C.G. Goo J.M. Heymach J. Hirsch F.R. Horinouchi H. Kerr K. Kris M. Jain D. Kim Y.T. Lopez-Rios F. Lu S. Mitsudomi T. Moreira A. Motoi N. Nicholson A.G. Oliveira R. Papotti M. Pastorino U. Paz-Ares L. Pelosi G. Poleri C. Provencio M. Roden A.C. Scagliotti G. Swisher S.G. Thunnissen E. Tsao M.S. Vansteenkiste J. Weder W. Yatabe Y. IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J. Thorac. Oncol. 2020 15 5 709 740 10.1016/j.jtho.2020.01.005 32004713
    [Google Scholar]
  23. Ostoros G. Hettle R. Georgoulia N. Berktas M. Chander P. Perez D.I. Couto A.M. Eichinger C. Field P. Morten P. Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: A systematic review and meta-analysis. Expert Rev. Anticancer Ther. 2023 23 12 1305 1313 10.1080/14737140.2023.2272645 37850939
    [Google Scholar]
  24. Kim Y.H. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N. Engl. J. Med. 2019 380 10 989 990 10.1056/NEJMc1900407 30855760
    [Google Scholar]
  25. Matsuda A. Yamaoka K. Kunitoh H. Seto T. Tsuboi M. Ohira T. Maruyama R. Okamoto H. Kubota K. Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503. Qual. Life Res. 2023 32 9 2629 2637 10.1007/s11136‑023‑03424‑y 37126140
    [Google Scholar]
  26. Wang H. Mou S. Tu M. Study on the effect of nano albumin paclitaxel combined with carboplatin in the treatment of lung squamous cell carcinoma. J. Nanosci. Nanotechnol. 2020 20 12 7439 7443 10.1166/jnn.2020.18880 32711612
    [Google Scholar]
  27. Gan J. Huang Y. Fang W. Zhang L. Research progress in immune checkpoint inhibitors for lung cancer in China. Ther. Adv. Med. Oncol. 2021 13 17588359211029826 10.1177/17588359211029826 34349843
    [Google Scholar]
  28. Wang J. Li J. Cai L. Chen S. Jiang Y. The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer. Ann. Transl. Med. 2021 9 6 486 10.21037/atm‑21‑670 33850883
    [Google Scholar]
  29. Patel S.A. Gibson M.K. Deal A. Sheth S. Heiling H. Johnson S.M. Douglas K. Flores M. Blumberg J. Lumley C. Yarbrough W.G. Shen C. Chera B.S. Bauman J.R. Hackman T. Weiss J. A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma. Cancer 2023 129 21 3381 3389 10.1002/cncr.34930 37395170
    [Google Scholar]
  30. Provencio M. Nadal E. Insa A. Campelo G.M.R. Rubio C.J. Dómine M. Majem M. Abreu R.D. Martí M.A. De Carpeño C.J. Cobo M. Vivanco L.G. Barco D.E. Caro B.R. Viñolas N. Aranda B.I. Viteri S. Pereira E. Royuela A. Casarrubios M. Antón S.C. Parra E.R. Wistuba I. Calvo V. Briviesca L.R. Romero A. Massuti B. Bermúdez C.A. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020 21 11 1413 1422 10.1016/S1470‑2045(20)30453‑8 32979984
    [Google Scholar]
/content/journals/pra/10.2174/0115748928304000240429120252
Loading
A Single-arm, Open-label, Phase Ib Clinical Study Evaluating the Efficacy andSafetyofDurvalumabinCombinationwithAlbumin-bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-small Cell Lung Cancer
Bentham Science Publishers ; https://doi.org/10.2174/0115748928304000240429120252
/content/journals/pra/10.2174/0115748928304000240429120252
/content/journals/pra/10.2174/0115748928304000240429120252
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: negative driver gene ; adverse reactions ; carboplatin ; nab-paclitaxel ; pathological response rate ; durvalumab ; Non-small cell lung cancer

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test